- Home
- SNN vs RPRX Comparison
SNN vs RPRX Comparison
Compare SNN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- RPRX
- Stock Information
- Founded
- SNN 1856
- RPRX 1996
- Country
- SNN United Kingdom
- RPRX United States
- Employees
- SNN N/A
- RPRX N/A
- Industry
- SNN Industrial Specialties
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SNN Health Care
- RPRX Health Care
- Exchange
- SNN Nasdaq
- RPRX Nasdaq
- Market Cap
- SNN 13.2B
- RPRX 15.6B
- IPO Year
- SNN 1999
- RPRX 2020
- Fundamental
- Price
- SNN $37.42
- RPRX $35.87
- Analyst Decision
- SNN Hold
- RPRX Strong Buy
- Analyst Count
- SNN 3
- RPRX 3
- Target Price
- SNN $31.50
- RPRX $45.33
- AVG Volume (30 Days)
- SNN 900.3K
- RPRX 3.1M
- Earning Date
- SNN 10-30-2025
- RPRX 08-06-2025
- Dividend Yield
- SNN 1.96%
- RPRX 2.45%
- EPS Growth
- SNN 59.91
- RPRX 54.86
- EPS
- SNN 0.56
- RPRX 2.32
- Revenue
- SNN $5,944,000,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- SNN $7.75
- RPRX $33.77
- Revenue Next Year
- SNN $5.37
- RPRX $4.62
- P/E Ratio
- SNN $33.13
- RPRX $15.45
- Revenue Growth
- SNN 5.35
- RPRX 3.02
- 52 Week Low
- SNN $23.69
- RPRX $24.05
- 52 Week High
- SNN $37.65
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- SNN 70.69
- RPRX 42.45
- Support Level
- SNN $37.02
- RPRX $35.48
- Resistance Level
- SNN $37.65
- RPRX $36.99
- Average True Range (ATR)
- SNN 0.34
- RPRX 0.68
- MACD
- SNN -0.12
- RPRX -0.14
- Stochastic Oscillator
- SNN 80.12
- RPRX 7.28
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.